Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 977 5700

Website: apellis.com

Address:

100 Fifth Avenue, Waltham, United States

The_Fudster Jun. 16 at 7:58 PM

$APLS maybe APLS and SRPT should get married? Honestly, it's kind of a compelling rare disease portfolio between the two of them. APLS doesn't have a pipeline, but SRPT does via the ARWR deal. And honestly, both could use a re-brand at this point.

1 · Reply

JenniFUR2 Jun. 16 at 3:18 PM

$APLS Thought I'd check in......this is where I usually buy again, then it tanks to sub $17.50...soooooo NOT this time.....

0 · Reply

scott52 Jun. 16 at 2:22 PM

$APLS Six weeks til PDUFA. Feels like an eternity.

1 · Reply

Whiskeyunderthebed Jun. 12 at 3:09 PM

$APLS frozen in time...

2 · Reply

Spanner1968 Jun. 11 at 8:58 PM

$APLS 1m AH...... and so saga continues

0 · Reply

Whiskeyunderthebed Jun. 11 at 3:39 PM

$APLS we definitely need a activist to intervene here (like $NVO) to take Cedric out of this equation.

0 · Reply

The_Fudster Jun. 11 at 2:55 PM

$APLS both amazing and extremely depressing to watch BBIO, MDGL, VRNA, TGTX, etc. out there crushing it. Us? Not even close.

1 · Reply

Whiskeyunderthebed Jun. 11 at 2:20 PM

$APLS stock is still red?

2 · Reply

Reneejordan001 Jun. 11 at 1:23 PM

$APLS A 1M buy in premarket...interesting

0 · Reply

Georgeson Jun. 11 at 4:08 AM

$APLS Let's hope for a good presentation! Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET.

1 · Reply

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 4, 2025, 7:00 AM EDT - 13 days ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:28 AM EDT - 27 days ago

Apellis Pharmaceuticals: Have Some Patience

May 7, 2025, 1:18 PM EDT - 5 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 5 weeks ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 weeks ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 30, 2025, 7:00 AM EDT - 6 weeks ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 2 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 1, 2025, 2:11 PM EDT - 2 months ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 2 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 3 months ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 3 months ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:05 AM EST - 3 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 2:00 AM EST - 4 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Feb 14, 2025, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 4:05 PM EST - 4 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 27, 2025, 4:00 PM EST - 5 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Jan 21, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Jan 20, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Jan 19, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Jan 13, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Jan 13, 2025, 9:00 AM EST - 5 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Jan 9, 2025, 10:00 AM EST - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

Jan 6, 2025, 12:30 PM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out

Jan 6, 2025, 7:00 AM EST - 5 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 5, 2024, 3:14 PM EST - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:05 AM EST - 7 months ago

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 26, 2024, 2:00 PM EDT - 8 months ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Oct 16, 2024, 2:56 PM EDT - 8 months ago

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Oct 4, 2024, 5:31 AM EDT - 9 months ago

Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)

Oct 3, 2024, 12:16 PM EDT - 9 months ago

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Oct 1, 2024, 1:15 PM EDT - 9 months ago

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Sep 25, 2024, 7:00 AM EDT - 9 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

Sep 20, 2024, 5:00 AM EDT - 9 months ago

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

Aug 9, 2024, 5:51 AM EDT - 11 months ago

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 8, 2024, 12:53 PM EDT - 11 months ago

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

Aug 8, 2024, 7:29 AM EDT - 11 months ago

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Aug 1, 2024, 5:59 PM EDT - 11 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:05 AM EDT - 11 months ago

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

The_Fudster Jun. 16 at 7:58 PM

1 · Reply

JenniFUR2 Jun. 16 at 3:18 PM

$APLS Thought I'd check in......this is where I usually buy again, then it tanks to sub $17.50...soooooo NOT this time.....

0 · Reply

scott52 Jun. 16 at 2:22 PM

$APLS Six weeks til PDUFA. Feels like an eternity.

1 · Reply

Whiskeyunderthebed Jun. 12 at 3:09 PM

$APLS frozen in time...

2 · Reply

Spanner1968 Jun. 11 at 8:58 PM

$APLS 1m AH...... and so saga continues

0 · Reply

Whiskeyunderthebed Jun. 11 at 3:39 PM

$APLS we definitely need a activist to intervene here (like $NVO) to take Cedric out of this equation.

0 · Reply

The_Fudster Jun. 11 at 2:55 PM

$APLS both amazing and extremely depressing to watch BBIO, MDGL, VRNA, TGTX, etc. out there crushing it. Us? Not even close.

1 · Reply

Whiskeyunderthebed Jun. 11 at 2:20 PM

$APLS stock is still red?

2 · Reply

Reneejordan001 Jun. 11 at 1:23 PM

$APLS A 1M buy in premarket...interesting

0 · Reply

Georgeson Jun. 11 at 4:08 AM

1 · Reply

philosophernutz Jun. 10 at 6:26 PM

$APLS The Mofos at SOBI better bring the heat. If they get approval they better be proactive about the launch. None of this "weather" and "inventory" crap.

3 · Reply

Whiskeyunderthebed Jun. 10 at 4:14 PM

$APLS small cap bios are ripping and this dog still can't hunt.

0 · Reply

Georgeson Jun. 9 at 11:04 PM

$APLS https://www.biospace.com/drug-development/apellis-sobi-see-potential-best-in-class-efficacy-for-empaveli-in-rare-kidney-diseases

2 · Reply

buylowandwait Jun. 9 at 7:12 PM

$APLS Is there sign of life now? PDUFA is coming next month, maybe it is about time to drive this up in anticipation of approval and GA revenue growth? I am still patiently waiting....

1 · Reply

The_Fudster Jun. 9 at 6:44 PM

$APLS am I color blind or.... is the chart green? What is this?

1 · Reply

Whiskeyunderthebed Jun. 9 at 4:52 PM

$APLS when I look a the pathetic action it reminds me of this infomercial https://youtu.be/v1WMQYd6IwE?t=14

0 · Reply

Winning_calls Jun. 9 at 2:04 PM

$APLS 👋👋

0 · Reply

JenniFUR2 Jun. 9 at 1:56 PM

$APLS Apellis should recommend buying 10 shares of this dog to insomniacs......snooze fest.

1 · Reply

Winning_calls Jun. 9 at 12:01 PM

$APLS 👊👊🤞

0 · Reply

Winning_calls Jun. 9 at 3:42 AM

$APLS pick me up @ $18.50

0 · Reply

Georgeson Jun. 7 at 6:37 AM

$APLS Anybody know when Sobi will get EU approval? Wonder if it will before apls or after.

2 · Reply

Whiskeyunderthebed Jun. 6 at 7:42 PM

$APLS what a dog this is.

2 · Reply

Market Cap	2.37B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-25.32%
Debt to Equity Ratio	2.19

Volume	1,805,000
Avg Vol	2,682,366
Day's Range	N/A - N/A
Shares Out	125.68M
Stochastic %K	15%
Beta	0.68
Analysts	Strong Sell
Price Target	$36.00